Michael A. Liss, MD, PhD, MAS, FACS, presented “Restriction Spectrum Imaging Guided Biopsy” during the 2023 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on November 10, 2023, in Chicago, Illinois.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Liss, Michael A. “Restriction Spectrum Imaging Guided Biopsy.” November, 2023. Accessed Oct 2026. https://grandroundsinurology.com/restriction-spectrum-imaging-guided-biopsy/
Restriction Spectrum Imaging Guided Biopsy – Summary
Michael A. Liss, MD, PhD, MAS, FACS, discusses how Restriction Spectrum Imaging (RSI) Guided Biopsy can aid in processing and interpreting MRIs by reducing false positives and improving MRI distortion. Dr. Liss begins by describing the top current issues with MRI sequencing: varied positive predictive values and Apparent Diffusion Coefficient (ADC) distorting MRI results.
Dr. Liss then discusses the role of RSI-guided biopsy in mitigating the weaknesses of conventional MRI. He illustrates what an MRI sequence with RSI using compartmental, nuclear volume, and geometric filtering looks like.
Dr. Liss concludes with examples of RSI-MRI results in patients with different Gleason scores and inflammation. He compares the efficacy of RSI-MRI in differentiating between inflammatory and regular lesions and presents data that supports the use of RSI-MRI in lowering the frequency of false positive biopsies due to the misclassification of inflammatory lesions.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Michael A. Liss, MD, PhD, MAS, MBA, FACS, is a Professor of Urology and the Director of Clinical Trials in the Center for Microbiome Innovation at the University of California, San Diego, San Diego, California. Dr. Liss specializes in genitourinary cancers, including those of the kidney and prostate. His primary research interests include incorporating imaging and biomarker translational research into interventional clinical trials. Dr. Liss is an entrepreneur with three patent applications and the founder of Oncobiomix Inc., which focuses on the development of biomarker-based technologies in medicine.
